Evotec Se - Adr (EVO)
$4.89
+0.4
(+8.91%)▲
Evotec Se - Adr Key Statistics
Market Capitalization | $1.7B |
Revenue TTM | $777.1M |
EBITDA | $15.9M |
Earnings Per Share (EPS) | $-0.52 |
Profit Margin | -22.05% |
Quarterly Earnings Growth YOY | 0.0% |
Return On Equity TTM | -16.25% |
Evotec Se - Adr share price movements
- $4.74$4.90$4.89
3.17%
Downside
Day's Volatility :3.37%
Upside
0.2%
- $2.85$12.00$4.89
41.72%
Downside
52 Weeks Volatility :76.25%
Upside
59.25%
Evotec Se - Adr Returns
| Period | Evotec Se - Adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 38.92% | -6.4% | 0.0% |
6 Months | 0.62% | 0.7% | 0.0% |
1 Year | -50.41% | 10.9% | 0.0% |
3 Years | -79.39% | 10.2% | -21.2% |
Analyst Recommendation on Evotec Se - Adr
- Current
- 1M Ago
- 3M Ago
Analyst Forecast on Evotec Se - Adr
What analysts predicted
Upside of 26.79%
Insights on Evotec Se - Adr
Increasing Revenue
Revenue is up for the last 2 quarters, 182.12M → 184.89M (in $), with an average increase of 1.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -94.93M → -39.63M (in $), with an average increase of 139.5% per quarter
Vs CTLT
In the last 1 year, Catalent, Inc. has given 53.3% return, outperforming this stock by 105.4%
Vs NBIX
In the last 3 years, Evotec Se - Adr has experienced a drawdown of -79.4%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 25.7%
Evotec Se - Adr Financials in INR & Dollars
| FY18 | Y/Y Change | |
|---|---|---|
Revenue | 427.0M | ↑ 45.71% |
Net Income | 95.7M | ↑ 247.0% |
Net Profit Margin | 22.42% | ↑ 13.0% |
| FY19 | Y/Y Change | |
|---|---|---|
Revenue | 496.1M | ↑ 18.92% |
Net Income | 42.4M | ↓ 54.67% |
Net Profit Margin | 8.55% | ↓ 13.87% |
| FY20 | Y/Y Change | |
|---|---|---|
Revenue | 609.3M | ↑ 12.2% |
Net Income | 7.6M | ↓ 83.55% |
Net Profit Margin | 1.25% | ↓ 7.3% |
| FY21 | Y/Y Change | |
|---|---|---|
Revenue | 698.7M | ↑ 23.38% |
Net Income | 243.6M | ↑ 3332.78% |
Net Profit Margin | 34.87% | ↑ 33.62% |
| FY22 | Y/Y Change | |
|---|---|---|
Revenue | 795.2M | ↑ 21.59% |
Net Income | -185.9M | ↓ 181.51% |
Net Profit Margin | -23.38% | ↓ 58.25% |
| FY23 | Y/Y Change | |
|---|---|---|
Revenue | 781.4M | ↑ 3.99% |
Net Income | -83.9M | ↓ 52.23% |
Net Profit Margin | -10.74% | ↑ 12.64% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 212.9M | ↓ 18.45% |
Net Income | -42.3M | ↑ 43.21% |
Net Profit Margin | -19.85% | ↓ 8.55% |
| Q3 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 209.5M | ↑ 0.0% |
Net Income | -41.6M | ↑ 0.0% |
Net Profit Margin | -19.85% | ↑ 0.0% |
| Q4 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 219.6M | ↑ 2.57% |
Net Income | -17.6M | ↓ 58.59% |
Net Profit Margin | -8.01% | ↑ 11.84% |
| Q1 FY24 | Q/Q Change | |
|---|---|---|
Revenue | 226.9M | ↑ 3.68% |
Net Income | -22.5M | ↑ 28.16% |
Net Profit Margin | -9.9% | ↓ 1.89% |
| Q2 FY24 | Q/Q Change | |
|---|---|---|
Revenue | 196.0M | ↓ 12.75% |
Net Income | -102.2M | ↑ 359.21% |
Net Profit Margin | -52.13% | ↓ 42.23% |
| Q3 FY24 | Q/Q Change | |
|---|---|---|
Revenue | 184.9M | ↑ 1.52% |
Net Income | -39.6M | ↓ 58.25% |
Net Profit Margin | -21.44% | ↑ 30.69% |
| FY18 | Y/Y Change | |
|---|---|---|
Total Assets | 878.0M | ↑ 15.68% |
Total Liabilities | 394.7M | ↑ 3.42% |
| FY19 | Y/Y Change | |
|---|---|---|
Total Assets | 1.3B | ↑ 52.99% |
Total Liabilities | 782.2M | ↑ 102.85% |
| FY20 | Y/Y Change | |
|---|---|---|
Total Assets | 1.8B | ↑ 23.88% |
Total Liabilities | 900.1M | ↑ 5.14% |
| FY21 | Y/Y Change | |
|---|---|---|
Total Assets | 2.5B | ↑ 52.79% |
Total Liabilities | 969.3M | ↑ 15.87% |
| FY22 | Y/Y Change | |
|---|---|---|
Total Assets | 2.4B | ↑ 0.99% |
Total Liabilities | 1.1B | ↑ 24.79% |
| FY23 | Y/Y Change | |
|---|---|---|
Total Assets | 2.5B | ↑ 1.85% |
Total Liabilities | 1.3B | ↑ 10.19% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 2.4B | ↓ 0.12% |
Total Liabilities | 1.2B | ↑ 4.08% |
| Q3 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 2.4B | ↑ 0.0% |
Total Liabilities | 1.2B | ↑ 0.0% |
| Q4 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 2.5B | ↑ 1.98% |
Total Liabilities | 1.3B | ↑ 5.88% |
| Q1 FY24 | Q/Q Change | |
|---|---|---|
Total Assets | 2.4B | ↓ 3.93% |
Total Liabilities | 1.2B | ↓ 6.53% |
| Q2 FY24 | Q/Q Change | |
|---|---|---|
Total Assets | 2.2B | ↓ 9.5% |
Total Liabilities | 1.1B | ↓ 10.41% |
| Q3 FY24 | Q/Q Change | |
|---|---|---|
Total Assets | 2.0B | ↓ 0.4% |
Total Liabilities | 1.0B | ↑ 3.54% |
| FY18 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 177.7M | ↑ 1342.93% |
Investing Cash Flow | -44.5M | ↓ 85.46% |
Financing Cash Flow | -88.5M | ↓ 132.3% |
| FY19 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 46.9M | ↓ 72.98% |
Investing Cash Flow | -96.3M | ↑ 121.4% |
Financing Cash Flow | 234.8M | ↓ 371.67% |
| FY20 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 54.4M | ↑ 5.93% |
Investing Cash Flow | -188.6M | ↑ 79.02% |
Financing Cash Flow | 299.7M | ↑ 16.64% |
| FY21 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 138.2M | ↑ 173.33% |
Investing Cash Flow | -275.7M | ↑ 57.24% |
Financing Cash Flow | 450.4M | ↑ 61.69% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 22.5M | ↓ 161.92% |
Investing Cash Flow | 15.6M | ↑ 0.0% |
Financing Cash Flow | 47.0M | ↓ 2312.65% |
| Q3 FY23 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 22.2M | ↑ 0.0% |
Investing Cash Flow | -16.8M | ↓ 209.48% |
Financing Cash Flow | 46.3M | ↑ 0.0% |
Evotec Se - Adr Technicals Summary
Sell
Neutral
Buy
Evotec Se - Adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Evotec Se - Adr Vs Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Evotec Se - Adr | 26.68% | 0.62% | -50.41% | -79.39% | -77.77% |
 Neurocrine Biosciences Inc. | 9.39% | -9.52% | 12.47% | 46.14% | 10.41% |
 Haleon Plc Spon Ads | -4.01% | 14.18% | 11.14% | 29.28% | 29.28% |
 Zoetis Inc. | -2.22% | 4.33% | -0.04% | -18.52% | 46.62% |
 Viatris Inc. | 13.61% | 28.59% | 43.04% | 4.78% | -18.24% |
 Catalent, Inc. | 4.22% | 13.5% | 56.71% | -53.68% | 16.37% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Evotec Se - Adr | 485.75 | NA | NA | -0.78 | -0.16 | -0.02 | NA | 5.46 |
Neurocrine Biosciences Inc. | 33.6 | 33.6 | 0.3 | 6.54 | 0.16 | 0.12 | NA | 26.87 |
Haleon Plc Spon Ads | 29.24 | 29.24 | 1.74 | 0.34 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 33.2 | 33.2 | 2.46 | 5.87 | 0.47 | 0.15 | 0.01 | 11.59 |
Viatris Inc. | 224.4 | NA | 0.08 | 2.67 | -0.04 | 0.02 | 0.04 | 16.58 |
Catalent, Inc. | 211.02 | NA | 508.17 | 0.2 | -0.11 | 0.0 | NA | 19.52 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Evotec Se - Adr | Buy | $1.7B | -77.77% | 485.75 | -22.05% |
Neurocrine Biosciences Inc. | Buy | $12.7B | 10.41% | 33.6 | 17.21% |
Haleon Plc Spon Ads | Buy | $43.6B | 29.28% | 29.24 | 10.75% |
Zoetis Inc. | Buy | $79.8B | 46.62% | 33.2 | 26.55% |
Viatris Inc. | Hold | $15.1B | -18.24% | 224.4 | -5.87% |
Catalent, Inc. | Hold | $11.1B | 16.37% | 211.02 | -9.34% |
Evotec Se - Adr Institutional Holdings
Novo A/S
4.18%Mubadala Investment Company PJSC
1.29%Wellington Management Company LLP
0.57%Morgan Stanley - Brokerage Accounts
0.07%DCF Advisers, LLC
0.06%Millennium Management LLC
0.05%
Company Information about Evotec Se - Adr
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.
Organization | Evotec Se - Adr |
Employees | 5007 |
CEO | Ms. Laetitia Rouxel |
Industry | Miscellaneous |
Discover More
Arc Document Solutions Inc
$4.89
+8.91%
Tmt Acquisition Corp
$4.89
+8.91%
Oculis Holding Ag
$4.89
+8.91%
Perma-fix Environmental Services Inc
$4.89
+8.91%
Citizens & Northern Corp
$4.89
+8.91%
Direxion Daily Gold Miners Index Bear 2x Shares Etf
$4.89
+8.91%
Zkh Group Ltd.
$4.89
+8.91%
Cambria Shareholder Yield Etf
$4.89
+8.91%
Everi Holdings Inc
$4.89
+8.91%